Matthew B Klein's most recent trade in ClearPoint Neuro Inc was a trade of 21,093 Common Stock done . Disclosure was reported to the exchange on May 16, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 50,518 (0%) | 0% | - | Common Stock | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 May 2025 | 21,093 | 0 | - | - | Restricted Stock Units | |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 48.74 per share. | 22 Apr 2025 | 2,804 | 273,234 (0%) | 0% | 48.7 | 136,656 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.10 per share. | 19 Feb 2025 | 3,897 | 279,933 (0%) | 0% | 50.1 | 195,224 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 19 Feb 2025 | 3,895 | 276,038 (0%) | 0% | 50.1 | 195,233 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 07 Jan 2025 | 2,402 | 283,830 (0%) | 0% | 44.5 | 106,889 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.34 per share. | 07 Jan 2025 | 2,142 | 286,232 (0%) | 0% | 45.3 | 97,118 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 70,000 | 288,374 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 45.16 per share. | 31 Dec 2024 | 8,279 | 217,528 (0%) | 0% | 45.2 | 373,880 | Common Stock |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 21,093 | 21,093 | - | - | Restricted Stock Units | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 0 | - | - | Restricted Stock Units | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 17,153 | 29,425 (0%) | 0% | - | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 24.89 per share. | 19 Apr 2024 | 3,361 | 225,807 (0%) | 0% | 24.9 | 83,669 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 25.13 per share. | 17 Apr 2024 | 1,307 | 229,168 (0%) | 0% | 25.1 | 32,851 | Common Stock |
PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 70,000 | 230,475 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Klein Matthew B. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 29.01 per share. | 08 Jan 2024 | 5,443 | 160,475 (0%) | 0% | 29.0 | 157,928 | Common Stock |
PTC Therapeutics Inc | B. Matthew Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 28.64 per share. | 08 Jan 2024 | 2,237 | 165,918 (0%) | 0% | 28.6 | 64,068 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 27.15 per share. | 05 Jan 2024 | 10,107 | 168,155 (0%) | 0% | 27.1 | 274,393 | Common Stock |
PTC Therapeutics Inc | Matthew Klein B. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Dec 2023 | 75,000 | 177,961 (0%) | 0% | 0 | Common Stock | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 17,153 | 17,153 | - | - | Restricted Stock Units | |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Apr 2023 | 26,000 | 103,856 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 52.04 per share. | 18 Apr 2023 | 1,211 | 102,645 (0%) | 0% | 52.0 | 63,025 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.93 per share. | 10 Jan 2023 | 2,273 | 80,100 (0%) | 0% | 42.9 | 97,586 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 44.36 per share. | 10 Jan 2023 | 2,244 | 77,856 (0%) | 0% | 44.4 | 99,543 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 41.66 per share. | 09 Jan 2023 | 731 | 82,373 (0%) | 0% | 41.7 | 30,451 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 65,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 26,000 | 83,104 (0%) | 0% | 0 | Common Stock | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 9,269 | 12,272 (0%) | 0% | 0 | Common Stock | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 6,179 | 6,179 | - | - | Stock Options (right to buy) | |
PTC Therapeutics Inc | Matthew B. Klein | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 42.52 per share. | 19 Apr 2022 | 897 | 56,564 (0%) | 0% | 42.5 | 38,136 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 21,000 | 37,461 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 20,000 | 57,461 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 38.53 per share. | 07 Jan 2022 | 775 | 16,461 (0%) | 0% | 38.5 | 29,857 | Common Stock |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 6,006 | 6,006 | - | - | Stock Options (right to buy) | |
ClearPoint Neuro Inc | Matthew B. Klein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 3,003 | 3,003 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 46.58 per share. | 19 Apr 2021 | 1,444 | 17,006 (0%) | 0% | 46.6 | 67,264 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 48.17 per share. | 19 Apr 2021 | 859 | 18,450 (0%) | 0% | 48.2 | 41,376 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 47.92 per share. | 19 Apr 2021 | 197 | 16,809 (0%) | 0% | 47.9 | 9,440 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.09 per share. | 15 Jan 2021 | 4,300 | 19,309 (0%) | 0% | 69.1 | 297,078 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 15 Jan 2021 | 4,300 | 23,609 (0%) | 0% | 39.0 | 167,614 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2021 | 4,300 | 86,314 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 08 Jan 2021 | 5,500 | 24,809 (0%) | 0% | 39.0 | 214,390 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jan 2021 | 5,500 | 90,614 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 69.48 per share. | 08 Jan 2021 | 4,000 | 20,809 (0%) | 0% | 69.5 | 277,924 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 70.32 per share. | 08 Jan 2021 | 1,500 | 19,309 (0%) | 0% | 70.3 | 105,486 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 52,500 | 52,500 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2021 | 9,000 | 19,309 (0%) | 0% | 0 | Common Stock | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2021 | 3,886 | 96,114 | - | - | Stock Option (Right to Buy) | |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.98 per share. | 06 Jan 2021 | 3,886 | 23,195 (0%) | 0% | 39.0 | 151,476 | Common Stock |
PTC Therapeutics Inc | Matthew B. Klein | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 68.98 per share. | 06 Jan 2021 | 3,886 | 19,309 (0%) | 0% | 69.0 | 268,056 | Common Stock |